Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification - Authors' reply
- PMID: 36098316
- DOI: 10.1016/S2666-7568(22)00112-X
Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification - Authors' reply
Conflict of interest statement
REP declares grants to his institution from Hanmi Pharmaceutical, Janssen, Metavention, Novo Nordisk, Poxel, and Sanofi; consulting fees to his institution from AstraZeneca, Bayer, Corcept Therapeutics, Dexcom, Gasherbrum Bio, Glytec, Hanmi Pharmaceutical, Hengrui (USA), Janssen, Merck, Mundipharma, Novo Nordisk, Pfizer, Rivus Pharmaceuticals, Sanofi, Scohia Pharma, and Sun Pharmaceutical Industries; and travel expenses from AstraZeneca, Glytec, Merck, Mundipharma, Novo Nordis, and Pfizer. AC declares no competing interests.
Comment on
-
Can technology improve the management of older adults with type 1 diabetes? Yes, but….Lancet Healthy Longev. 2022 Mar;3(3):e120-e121. doi: 10.1016/S2666-7568(22)00032-0. Lancet Healthy Longev. 2022. PMID: 36098285 No abstract available.
-
Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification.Lancet Healthy Longev. 2022 Jun;3(6):e378. doi: 10.1016/S2666-7568(22)00092-7. Epub 2022 Jun 9. Lancet Healthy Longev. 2022. PMID: 36098315 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
